Brand Drift | MedicinMan
Brand Drift | MedicinMan
Tuesday, September 1, 2026
28.2
C
Bengaluru
Hot topics
Will Omicron Wave be a Repeat Rx for Indian Pharma?
How had Indian Pharma responded to the challenges brought on by the Covid19 crisis and the inability to connect with doctors and other Rx influencers?
Is it back to business-as-usual or have some companies learned from their mistakes and become digital savvy?
How will Indian Pharma cope with the possibility of another lockdown and meeting restrictions looming in view of the rising Omicron wave?
How a Delhi Dementia Daycare Is Reimagining Care for India’s Forgotten Millions
By MedicinMan Editorial Desk
When Memory Fades, Humanity Must Not
In...
Navigating the Jungle: How to Turn Field Chaos Into Your Brand’s Competitive Advantage
To navigate chaos, you first need to know who...
Sales Readiness For Trainers and Reps – Improve Effectiveness In A New Pharma World
Last week, I was in a meeting with the...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Hot topics
Debasish Banerjee’s Journey from Medical Rep to Chief Compliance Officer
For a person wanting to be a doctor, my...
Cipla’s Leadership Transition from Umang Vohra to Achin Gupta: Succession Planning in Action
By Anup Soans | MedicinMan
Cipla Limited has announced a...
The Killer Nexus – What Really Ails Indian Healthcare?
For Every Bottle Of Killer Cough Syrup Doctor Prescribed,...
IMS Health Market Reflection Report for June 2016
Every month, MedicinMan in partnership with IMS Health, brings our readers the latest industry numbers related to sales and revenues of different companies, brands and therapy areas in the Indian Pharmaceutical Market.
Indian Pharma in September 2025: Momentum, Disruption & Caution
Indian Pharma in September 2025: Momentum, Disruption & Caution
By...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
Newsletter
Get important news delivered directly to your inbox and stay connected!